This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As the world of diabetestech continues to advance, the bad impact of these choice restrictions becomes even more obvious. Still, this announcement is a positive step toward opening up the market to allow people living with diabetes the opportunity to finetune their treatment based on what works for them.
The iLet trial can serve as a reminder to the diabetestech community that while the 670G may be an important introduction to the era of artificial pancreas technology, it will not be the final word. This trial involved 124 people with Type 1 diabetes, ages 14 to 75.
For people living with diabetes who aren’t part of a rigorous scientific study, completely avoiding lows can be close to impossible. Improvements in diabetestech are making it more possible to reduce the occurrence of hypos without sacrificing tight control over blood sugars. Lows will happen.
Of course, this was a singular example—one person, one sensor, nothing conclusive—and there is certainly room for improvement in my algorithm that can only really be done with large amounts of data. Insulin Nation takes no position on DIY diabetestech hacks. That is why I am not waiting. Devices Meters & CGMs'
Of course, this was a singular example—one person, one sensor, nothing conclusive—and there is certainly room for improvement in my algorithm that can only really be done with large amounts of data. Insulin Nation takes no position on DIY diabetestech hacks. That is why I am not waiting. Devices Meters & CGMs'
Instead, he ran straight for the kitchen and began chugging root beers and feverishly eating cookies to offset the flood of insulin now coursing through his veins. The veteran diabetic had managed to stave off a serious emergency and live to see another day. . For Tim, this was everything. .
While educating people is always the optimal course of action, it isn’t always possible or worth your energy. Diabetes is not fun, but there are a lot of conditions out there that are a lot more debilitating, life-altering, and deadly. Try to remember that there was probably a time when you shared a similar misunderstanding.
Studies have shown that diabetics with supportive partners often achieve better glycemic control than those without. Of course, complications aren’t only seen in long-term relationships. And that those who have experienced severe hypoglycemic episodes see higher stress levels and more arguments within their relationships. . Technology.
Additional data were collected at pre-scheduled intervals over the course of six months. The persistence of ketone-inducing hyperglycemia even when utilizing such a high-tech piece of equipment is frustrating. Base data was also collected from each patient at the beginning of the study period.
The Importance of Affordable Diabetes Supplies. Insulin, of course, is the one thing no person with type 1 can live without. Of course, the most notable new development for treating type 1 is the use of automated insulin delivery (AID) systems that utilize both a pump and CGM.
If the past year is any indication, diabetestech geeks might have to work hard in 2017 to keep up with the latest models of pumps and CGMs on the marketplace. As Diabetes Mine reported at the time of the G5 approval, the swiftness of FDA approval caught even Dexcom execs off-guard.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content